TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Health & Fitness

    Cardionerds: A Cardiology Podcast

    Welcome to CardioNerds, where we bring you in-depth discussions with leading experts, case reports, and updates on the latest advancements in the world of cardiology. Tune in to expand your knowledge, sharpen your skills, and become a true CardioNerd!

    Advertise
    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    154. Cardiology vs Nephrology: A Diuretic Showdown with Dr. Michael Felker & Dr. Matt Sparks Oct 11, 2021
    Show notes

    CardioNerds, Amit Goyal and Daniel Ambinder, join Duke University CardioNerds Ambassador and Correspondent, Dr. Kelly Arps for the diuretic showdown of a lifetime. Join us for this Cardiology vs. Nephrology discussion and respective approach to volume overload and diuretic strategies with Dr. Michael Felker (Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine), and Dr. Matt Sparks (Founding member of the Nephrology Social Medial Collective and #NephJC and Associate Professor of Medicine and Program Director for the Nephrology Fellowship Program at Duke University School of Medicine). Episode introduction, audio editing and Approach to Diuretic Resistance infographic by Dr. Gurleen Kaur (Director of the CardioNerds Internship). Volume overload is a common indication for hospitalization in patients with heart failure. Loop diuretics are first line therapy for volume overload in heart failure, with assessment for adequate response within 3-6 hours after administration. Elevation in creatinine is common with venous congestion as well as during decongestion. While other causes of renal injury should be considered, an elevated creatinine in this context should not automatically trigger avoidance or cessation of diuresis. Diuretic resistance is an exaggerated form of natural safety mechanisms in the face of diuresis. Strategies for addressing diuretic resistance include optimizing dose and frequency of loop diuretic administration, adding adjunctive medication for sequential nephron blockade (i.e., thiazide diuretic, potassium sparing diuretic, acetazolamide, tolvaptan, SGLT2 inhibitor), and, in refractory cases, hemodialysis with ultrafiltration. In the outpatient setting, transition to a more potent loop diuretic (i.e., torsemide or bumetanide from furosemide), addition of a mineralocorticoid antagonist, or intermittent dosing of thiazide diuretic may augment maintenance diuretic therapy for patients with diminished response to loop diuretics. Check out the CardioNerds Failure Heart Success Series Page for more heart success episodes and content! Relevant disclosures: None Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! The CardioNerds Heart Success Series is developed in collaboration with the Heart Failure Society of America. The Heart Failure Society of America is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org. Pearls - Cardiology vs Nephrology: A Diuretic Showdown Elevation in creatinine is expected in both congested states and during diuresis. Do not avoid or stop diuresis in a patient who is clearly volume overloaded based on an elevated creatinine. There may be a role for right heart catheterization if the fluid and/or hemodynamic status is unclear. Alkalosis in the setting of loop diuretic administration and diuretic resistance may represent a natural response to loop diuretics and not volume depletion. Ensure adequate potassium repletion and try using a mineralocorticoid antagonist to correct this alkalosis. Acetazolamide is rarely necessary but may be of use.Currently available evidence does not support extreme fluid or salt restriction in hospitalized patients with volume overload. Consider permissive restrictions and focus on choosing appropriate diuretic dosing for each individual patient. Diuretic resistance is an exaggerated form of diuretic braking, the kidney’s natural response to prevent dangerous degrees of sodium loss from the NKCC2-blocking effects of loop diuretics. Torsemide has improved bioavailability and duration of action compared to furosemide and may be a good choice for outpatient therapy in patients with limited diuretic response. Quotable - Cardiology vs Nephrology: A Diuretic Showdown Permissive hypercreatinemia Eventually the…body recognizes that, Hey, if we're going to live without this very important, cotransporter in KCC2, we're going to have to kick on things in the distal nephron to basically have a steady state. - Dr. Sparks I would rather the patient feel good with a creatinine of 2 than terrible with creatinine of 1 and a half. - Dr. Felker I think it's pretty clear that in the long run, if they're accompanied by effective decongestion, [minor elevations in creatinine] are actually if anything, a favorable prognostic indicator in terms of heart failure, prognosis, as opposed to an adverse one. - Dr. Felker I think we hit a record for that. The most number of times a cardiologist has mentioned urine and measuring something in the urine. - Dr. Sparks I can tell you my experience and it's biased because I take care of people with pretty bad heart failure, but nine times out of 10, if we do a right-heart cath, because we're not sure if the patient is still volume overloaded, they still are. - Dr. Felker The more, when you look at the data, the more high quality, the study design, so randomized versus non-randomized, uh, the worst sodium and fluid restriction look. The one thing we are guaranteed to do though, is create unhappy patients. - Dr. Felker Show notes - Cardiology vs Nephrology: A Diuretic Showdown 1. Approach to diuretic therapy for inpatients with volume overload Evaluate for non-cardiac sources of edema (nephrotic syndrome, hepatic dysfunction, VTE, etc).Choose a starting dose of loop diuretic. The effective home dose is a helpful guide.Evaluate diuretic response within 2-3 hours of each dose. If inadequate response, double the next dose of loop diureticIf inadequate or diminishing response to high-dose loop diuretic, consider additional pharmacotherapies (discussed below) Consider right heart catheterization whenConcerned for low output state Exam is unclear for volume status 2. Initial dose of diuretic therapy for hospitalized patients The kidney alters its compensatory mechanisms to avoid being poisoned by too much blockade of important transporters like NKCC-2 (loop diuretic) and NCC (thiazide diuretics). Start with at least double the patient’s maintenance dose of diuretic Patients on chronic high-dose diuretics need higher initial IV dosesPatients with CKD need higher doses of diuretic 3. Evaluating for adequate response to diuretic in a hospitalized patient 2-3 hours after the dose: Urine output: should be >150 mL / hour in the 2-3 hours after an adequate diuretic dose. Spot urine sodium: should be >50-70 mmol/L after an adequate diuretic dose Daily: assess for improvement in jugular venous distension, lower extremity edema, weight, calculated ratio of fluid intake to output, and symptoms (orthopnea, dyspnea on exertion). 4. Approach to elevated creatinine in a volume overloaded patient Evaluate for alternative causes of hypercreatinemia: urinary obstruction, nephrotoxic agents (i.e. IV contrast, antibiotics, NSAIDs). If exam and/or invasive hemodynamic data are consistent with volume overload, renal vascular congestion may be contributing to elevated creatinine, and is expected to improve with euvolemia. 5. Approach to ‘contraction alkalosis’ in a patient undergoing diuresis Alkalosis in the setting of loop diuretic administration and diuretic resistance may not indicate volume depletion. Diuretics increase delivery of sodium to the distal nephron, which accelerates potassium and proton secretion and results in bicarbonate reclamation, resulting in hypokalemic metabolic alkalosis. Diuresis triggers activation of the renin-angiotensin system, which increases apical ATPase activity, increasing hydrogen ion secretion into the urine. Repleting potassium (with potassium chloride, not potassium citrate) can correct metabolic alkalosis. Use of mineralocorticoid receptor antagonists can improve this metabolic alkalosis.Acetazolamide may be used in refractory cases with severe metabolic alkalosis. 6. Approach to hyponatremia in heart failure Consider reasonable degree of fluid restriction (available evidence does not support extreme fluid restriction. Pharmacotherapy options for extreme hyponatremia includes urea and tolvaptan. 7. Causes of diuretic resistance Processes outside the nephron: venous congestion, low-output heart failure, hypoalbuminemia, increased intraabdominal pressureIntra-renal causes (response to sodium loss, caused by NKCC2 blockade by loop diuretics): reflexive upregulation of sodium intake in the proximal tubule, increased expression of sodium reabsorption channels (e.g., ENAC, NCC, pendrin) 8. Treatment options for diuretic resistance Increase dose +/- frequency of loop diureticThiazide diuretic (and monitor electrolytes closely)Potassium sparing diuretic (i.e., spironolactone, amiloride)Tolvaptan SGLT2 inhibitor (“a diuretic enabler”) Oral loop diuretics FurosemideBumetanideTorsemidePO: IV conversion~2:11:11:1Dose ratio (to furosemide)---1:401:2Bioavailability in oral dosingWidely variableNearly 100%Nearly 100% References - Cardiology vs Nephrology: A Diuretic Showdown Reviews Ellison DH, Felker GM. Diuretic Treatment in Heart Failure [published correction appears in N Engl J Med. 2018 Feb 1;378(5):492]. N Engl J Med. 2017;377(20):1964-1975. doi:10.1056/NEJMra1703100 Felker GM, Ellison DH, Mullens W, Cox ZL, Testani JM. Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(10):1178-1195. doi:10.1016/j.jacc.2019.12.059 Trials 3T trial: Cox ZL, Hung R, Lenihan DJ, Testani JM....


    153. Case Report: Ur-Ine for a Treat – A Case of Diuretic Resistance – The Johns Hopkins Hospital Oct 08, 2021
    Show notes

    CardioNerds (Amit Goyal and Daniel Ambinder), join Dr. Anjali Wagle (Internal medicine resident, Johns Hopkins Hospital) and Dr. Nick Smith (Cardiology fellow, Johns Hopkins Hospital) for an important discussion involving a patient with non-ischemic dilated cardiomyopathy and biventricular heart failure who had developed diuretic resistance. They discuss the role for invasive hemodynamic assessment of volume overload, initial strategies in managing a patient with volume overload, the role of guideline directed therapy in the management of patients with recurrent volume overload, and advanced strategies for diuretic resistance. Dr. Nisha Gilotra (Director of the Cardiac Sarcoidosis Program and assistant professor of medicine, Johns Hopkins Hospital) provides the E-CPR for this episode. Audio editing and Approach to Diuretic Resistance infographic by Dr. Gurleen Kaur (Director of the CardioNerds Internship). This episode is made possible with support from Panacea Financial. Panacea Financial is a national digital bank built for doctors by doctors. Visit panaceafinancial.com today to open your free account and join the growing community of physicians nationwide who expect more from their bank. Panacea Financial is a division of Primis, member FDIC. Claim free CME just for enjoying this episode! Disclosures: NoneJump to: Patient summary - Case teaching - References CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Patient Summary - Diuretic Resistance A young woman in her 20s with non-ischemic dilated cardiomyopathy and NYHA class IV ACC stage D biventricular heart failure with an LV ejection fraction of 30-35% on palliative inotropic therapy complicated by cardiogenic cirrhosis and stage IIIb chronic kidney disease presented with acute decompensated heart failure with volume overload. During her hospitalization she exhibited profound signs of diuretic resistance with minimal improvement after increasing inotropes, increasing IV loop diuretics, adding IV thiazides, and trialing continuous IV furosemide. She was given high dose mineralocorticoids, IV acetazolamide, and hypertonic saline paired with IV furosemide and had a durable treatment response. Episode Teaching - Diuretic Resistance Pearls - Diuretic Resistance Diuretic resistance is a complex clinical problem defined as inadequate natriuresis despite an adequate diuretic regimen. However, the practitioner cannot overlook low output heart failure and/or insufficient renal perfusion as the causes for inadequate diuretic response. In cases of inadequate urine output due to low cardiac output, increased inotropic or mechanical support would be the first objective.Confirming adequate cardiac output to support renal perfusion and/or confirming high filling pressures may require invasive hemodynamic assessment.Sodium avidity is most effectively blunted by treating the patient with maximally tolerated guideline directed therapy. This includes but is not limited to a backbone of ARNI (or ACE or ARB), mineralocorticoid receptor antagonists, beta-blockers, and SGLT-2 inhibitors.In cases of advanced diuretic resistance, hypertonic saline paired with high dose IV furosemide can be an effective strategy.In cases of diuretic resistance combined with cirrhosis and heart failure there is a synergistic hyperaldosteronism that can be targeted with higher doses of mineralocorticoid receptors as is seen in the treatment of cirrhosis with ascites. Notes - Diuretic Resistance 1. What is the role for invasive hemodynamic assessment in acute decompensated heart failure? Cases where intracardiac filling pressures are in question: right heart catheterization (RHC) can give insight into the presence and degree of right versus left sided filling pressures. We discussed the concepts of “RV equalizer” vs “RV compensated” groups in Episode 142 with Dr. Mark Drazner.Cases where cardiac output is in question, especially to guide vasoactive infusions during low flow states: RHC can assess cardiac output and cardiac power output.Cases with rising creatinine during diuresis despite a clinical exam suggesting volume overload.Cases where body habitus prevents optimal evaluation. 2. What are the initial strategies in managing a patient with volume overload? Initial furosemide dosing: The patient’s home dose, renal function, and reason for decompensation all help decide the initial IV diuretic dosing. However, in general if a patient has an outpatient furosemide regimen, the initial diuretic dose should 2.5 times the oral dosing for intermittent IV doses. For example, if a patient is taking 40 mg PO daily as an outpatient, a starting dose of 100 mg IV as a starting dose is appropriate.Furosemide escalationIV dosing: constantly assess the appropriateness of each furosemide dose by monitoring hourly urine output and daily standing weight changes. Post-dose urine sodium is another option. If the patient has not made 300 cc/hr after their last furosemide dose, you may need to escalate the dose. Due to the furosemide threshold effect, the patient may need to double the prior dose for every uptitration. Additionally, even though furosemide lasts for 6 hours, if the diuretic effect is minimal, immediately prescribe double the last dose of furosemide.Continuous infusion vs bolus: The DOSE trial, or Diuretic Optimization Strategies Evaluation, randomized 308 patients to either IV furosemide q12 or an equivalent dose as a continuous infusion and found no difference in secondary endpoints of change in weight or net fluid loses. There may be a role for continuous infusion furosemide in patients who are sensitive to large fluid shifts, such as patients with right heart failure.Adjunctive diureticsThiazide diuretics: when high dose IV furosemide is failing, thiazide diuretics are commonly the first adjunct use. When given in combination with loop diuretics, they allow blockade of both the sodium-potassium-chloride channels in the loop as well as the sodium chloride channels distally to allow increased blockade of the ability to reabsorb sodium and potassium.Potassium sparing diuretics: the addition of potassium-sparing diuretics (i.e., mineralocorticoid receptor antagonists or ENaC inhibitors like amiloride or triamterene) may be especially helpful for hypokalemia caused by loop +/- thiazide diuretics.Acetazolamide: is a carbonic anhydrase inhibitor and acts in the proximal convoluted tubule. It aids in the excretion of sodium and bicarbonate. It is commonly, but not always, used in situations where serum bicarbonates become elevated. 3. What is the role of guideline directed therapy in the management of patients with recurrent volume overload? In short, maximally tolerated guideline directed therapy blunts sodium retention through multiple mechanisms, but none more so than blockers of the renin-angiotensin-aldosterone-system. By blocking aspects of this pathway, the kidneys’ propensity to reabsorb sodium is blunted upstream of the nephron, preventing some of the need for high dose diuretics. Individual GDMT therapies and some of their effects on diuretic dosing are explained below.ARNI (angiotensin receptor neprilysin inhibitor): post-hoc analysis of the PARADIGM trial demonstrated that patients were more likely to decrease diuretic dosing on ARNI compared to placebo. Other single center studies have demonstrated similar effects, finding that loop diuretic dosing decrease was achieved in 1/3 of patients with a mean reduction of 10±38 mg furosemide equivalent across the entire population. Conversely, be cautious of diuretic dosing when initiating a patient on an ARNI agent. Enjoy Episode 148 with Dr. Milton Packer discussing the history of ARNI!MRA: Post-hoc analysis of EPHESUS demonstrated that the mineralocorticoid receptor antagonist Eplerenone led to a mean furosemide equivalent dose reduction of −2.2 mg/day (−2.9 to −1.6) throughout the follow-upMADIT-CRT: A post-hoc analysis of the MADIT-CRT trial showed that CRT implant led to diuretic cessation in 9.7% of patients. In a subsequent retrospective study of 352 subjects on baseline diuretics, 36% of patients tolerated a down-titration of loop diuretic dose following CRT-implant. These effects appeared sustained and were associated with both an improved hemodynamic performance and decreased probability of HF or death.SGLT-2 inhibitors: SGLT-2 inhibitors have a modest diuretic effect through glycosuria. Post-hoc analysis of the DAPA-HF trial did not show reduction in diuretic requirements over the 18-month trial, however SGLT-2 inhibitors have been shown to lead to reduction in diuretic requirements when used in combination when used in combination with MRA, BB, and ARNI therapy as part of a GDMT regimen. 4. What are some advanced strategies for diuretic resistance? Dopamine: The ROPA-DOP trial was a small single center trial performed in hospitalized patients with acute decompensated heart failure with preserved ejection fraction. It showed that continuous low dose dopamine infusion had no significant impact on renal function or decongestion.High Dose Spironolactone: Post-hoc analyses of trials involving spironolactone have not demonstrated reductions in diuretic dosing. However, in patients with a combination of cirrhosis and heart failure the hyperaldosteronism that results can be profound. For these patients, natriuretic doses of aldosterone antagonists (spironolactone >50 mg/day) may be a potential option and have been studied in small proof-of-principle studies. The competitive natriuretic response of aldosterone antagonists is related to activity of the renin-angiotensin-aldosterone system: the higher the renin-angiotensin-aldosterone system activity,...


    152. Cardio-Obstetrics: Pregnancy and Multidisciplinary Critical Care with Drs. Afshan Hameed, Marie-Louise Meng, and Paul Forfia Oct 04, 2021
    Show notes

    CardioNerds (Amit Goyal and Daniel Ambinder), Cardio-OB series co-chair and University of Texas Southwestern Cardiology Fellow, Dr. Sonia Shah, episode lead fellow, Dr. Kaitlyn Ibrahim (Temple University now practicing with Lankenau Heart Group), join Dr. Afshan Hameed (Maternal-Fetal Medicine, Obstetrics & Gynecology, UC Irvine), Dr. Paul Forfia (Co-Director, Pulmonary Hypertension, Right Heart Failure & CTEPH Program, Temple University Hospital), and Dr. Marie-Louise Meng (Obstetric and Cardiothoracic Anesthesiology, Duke University) to discuss pregnancy and multidisciplinary critical care. Three experts from varied subspecialties including Cardiology, Pulmonary Hypertension, Maternal Fetal Medicine, Cardiac Anesthesia and Obstetrical Anesthesia guide listeners through a case of a patient with a congenital conotruncal ventricular septal defect, Eisenmenger physiology, and pulmonary hypertension who becomes pregnant. The discussion touches on pre-conception risk assessment, pulmonary hypertension medical therapy in pregnancy, maternal monitoring during pregnancy, development of detailed multidisciplinary delivery plans and accessibility of such plans, and peri- and post-partum multidisciplinary management of high-risk patients. Audio editing and episode introduction by CardioNerds Academy Intern, Christian Faaborg-Andersen. Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Cardio-Obstetrics Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Cyanotic congenital heart disease presents multiple risks to the fetus, the most significant being intrauterine growth restriction. In a patient with Eisenmenger physiology, maternal oxygenation should be monitored closely throughout pregnancy, as hypoxia is often a marker of increased right to left shunting in these patients.In patients with pulmonary hypertension, the RV-PA coupling relationship is the best indicator of maternal cardiovascular reserve through the pregnancy and post-partum period. The goal of therapy is to get the pulmonary vascular resistance down to a point where the right heart can adapt to that load and function either at a normal or a near-normal level.When a high-risk patient meets with Anesthesia, it is important to consider the A’s: 1. Airway (anticipating any potential difficulties); 2. Access (whether this may present a challenge at the time of delivery); 3. Anxiety (specifically differentiating true hemodynamic changes in high-risk patients versus physiologic changes from anxiety); 4. Anticoagulation (knowledge of what agent the patient is on to determine safety of neuraxial anesthesia); 5. Availability (determining who else needs to be in the room, i.e. CT surgery, cardiothoracic anesthesia, ECMO team); 6. Arena (where is the safest place for this patient to deliver).In patients with a shunt who undergo a Cesarean section, the uterus should not be exteriorized due to risk of venous micro air emboli.As Dr. Forfia says, “panic is more dangerous sometimes than pulmonary hypertension!” Meaning, it is important to meet as a multidisciplinary team to develop a clear, easily accessible delivery plan for the patient. It is also prudent to have “everyone functioning in the environment they function best” like delivering the baby on the labor and delivery floor where all the necessary equipment and team members are available and bringing in other experts if needed rather than a cardiac operating room. For a deep dive into Pregnancy & Pulmonary Hypertension, enjoy: Episode #124 with Dr. Candice Silversides.Episode #144 – Case Report: A Mother with Shortness of Breath Show notes 1. How does a multidisciplinary team play a role in the care for a high risk cardio-obstetrics patient, particularly one with congenital heart disease and pulmonary hypertension? According to the 2018 ESC guidelines, a multidisciplinary team is required to care for the pregnant patient with PH. This should include a PH expert at an experienced center for pregnancy and cardiac disease. Maternal outcomes in patients with PH have improved with targeted therapies as well as a multidisciplinary, team-based approach.A multidisciplinary team for a high-risk cardio-obstetrics patient should have representation from several subspecialties, typically including Cardiology (and in patients with PH, a PH expert should be included), Maternal Fetal Medicine, and Anesthesiology. Additional subspecialities can be added depending on the underlying diagnosis of the patient and any potential challenges anticipated at the time of delivery. (i.e. CT Surgery if ECMO may be needed).The key is consistent membership within the group for optimal team dynamics, working relationships, and continuity of patient care. Familiarity among group members helps to facilitate improved communication.Team members should be experienced in the care of high-risk cardio-obstetrics patients. As Dr. Forfia mentions during the podcast, panic can be the downfall of a well-functioning team in a high stake setting and is often dangerous to the patient.Frequent meetings should happen amongst group members to discuss patients and to form individualized, multidisciplinary delivery plans. The delivery plan should detail each aspect of labor and delivery, include the names and contact information of providers involved in the patient’s care, and should be easily accessible (ideally in a prominent location in the patient’s electronic medical record).If possible, providers should be allowed to work in their usual environment. For example, a high-risk patient should deliver on the L&D floor/L&D OR with OB/MFM and other members of the multidisciplinary team should come to that area. This ensures all necessary equipment and experienced staff will be present during the delivery. 2. What are the important considerations during the Anesthesia evaluation of a high-risk pregnant patient? When a high-risk patient meets with Anesthesia during pregnancy, the A’s should be considered, listed below:Airway: It is important to perform an assessment of the patient’s airway prior to delivery to anticipate any potential difficulties and to ensure that the appropriate equipment is available at the time of delivery if a difficult airway is anticipated.Access: Potential intravenous access sites should be assessed prior to delivery to determine whether access may present a challenge at the time of delivery.Anxiety: An Anesthesiologist for a high-risk patient should be adept at differentiating true hemodynamic alterations versus physiologic changes from anxiety to provide appropriate therapy and counseling.Anticoagulation: A subset of high-risk cardiac patients will be on chronic anticoagulation therapy during pregnancy. Knowledge of a patient’s anticoagulant is critical in determining the safety of neuraxial anesthesia. It is also important to highlight that Eisenmenger’s can lead to thrombocytopenia, which (if severe enough) can be a contraindication to neuraxial anesthesia.Availability: It is vital to determine who will need to be available for a high-risk patient’s delivery, particularly which specialists, but also which subspecialists (i.e. cardiac anesthesia, cardiologists with expertise in pulmonary hypertension, ECMO team etc.). This allows adequate planning and staffing at the time of delivery.Arena: The multidisciplinary team should discuss the best place for the patient to deliver (i.e. the L&D floor, L&D OR, cardiac OR) depending on the expected course of delivery. Often, it is best to have the patient delivery on a dedicated obstetrical floor and bring any necessary consultants there to ensure all necessary equipment for the delivery and experienced obstetrical staff are present. 3. What are some pearls for the multidisciplinary management of high-risk cardio-obstetrics patients and specifically those with pulmonary hypertension and a shunt lesion during delivery? As mentioned previously, a detailed delivery plan should be created in advance of delivery with input from the multidisciplinary team caring for the patient. This should be easily accessible by all team members at the time of delivery.Most of these patients should deliver by 37 weeks gestation at a center with cardiology and intensive care unit support if needed.Patients with pulmonary hypertension should avoid Valsalva/pushing as much as possible. This is accomplished by an assisted second stage of labor.Patients with uncorrected cyanotic congenital heart disease should be considered for antibiotic prophylaxis for endocarditis at the time of delivery.In patients with an intracardiac shunt, all intravenous lines should have filters to prevent paradoxical air embolism. Additionally, the OB team should avoid “exteriorizing” the uterus during a C-section due to risk of paradoxical air embolism. This is particularly important in right-to-left shunt lesions.Fetal heart rate can serve as the “5th vital sign” of the mother during the time of delivery and can add to the overall assessment of the mother and fetus.Specialized Anesthesia care may involve the insertion of a central line and/or arterial line for close hemodynamic monitoring during delivery and in the immediate post-partum period. 4. What are the interdisciplinary critical care considerations in the post-partum period for high-risk patients, and specifically those with pulmonary hypertension and shunt lesions? According to the 2018 ESC guidelines, the highest risk period is during puerperium and early post-partum where fluid shifts and hemodynamic changes are the greatest. As part of the delivery plan, immediate post-partum care should also be specified. Often high-risk patients may need to be monitored and managed in an ICU setting or on a Cardiology primary service with the OB/MF


    151. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 6 – Mentorship & The Secret to Immortality Sep 30, 2021
    Show notes

    CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 6 Dr. Packer reflects on a conversation he had with Dr. Eugene Braunwald about mentorship and its role in immortality. This episode is particularly meaningful to the CardioNerds team as mentorship and sponsorship is such an important part of the CardioNerds mission. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.


    150. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 5 – The Ejected Fraction Of A Destroyed Heart Sep 27, 2021
    Show notes

    CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 5, Dr. Packer shares his thoughts on the term “guideline directed medical therapy,” guidelines in general, and the challenges of using the ejection fraction to measure systolic function. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.


    149. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 4 – SGLT2 Inhibitors – Under-Promised & Over-Delivered Sep 27, 2021
    Show notes

    CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 4, Dr. Packer shares his perspective on the revolutionary SGLT2 inhibors. We discuss the mechanisms of action and the data regarding their role in the care of heart failure patients. This episode is particularly historic in that Dr. Packer shares his thoughts about the EMPEROR-PRESERVED trial well before the data was available. Also see Dr. Mark Belkin's DocWire News article EMPEROR’s New Groove? Empagliflozin Provides Long-Awaited Treatment for HFpEF where Dr. Packer is quoted as saying “we are pleased to have the first trial in patients with HFpEF that shows an unequivocally positive and clinically important result. We are looking forward to many secondary papers that will provide detailed information about what we have found, and what it means for patients.” Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.


    148. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 3 – Neutral Trials, A 2nd Chance, & A Paradigm Shift Sep 20, 2021
    Show notes

    CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 3 Dr. Packer reflects on the value of neutral trials and recounts the journey that led to the PARADIGM Trial Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.


    147. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 2 – The Secret To Happiness, The “Aha” Moment, & The Birth Of The Neurohormonal Hypothesis Sep 20, 2021
    Show notes

    CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 2 Dr. Packer shares his journey as the trailing spouse and tells the story of how the neurohormonal hypothesis was developed. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.


    146. The Evolution Of The Neurohormonal Hypothesis With Dr. Milton Packer: Part 1 – Taking Risks, Upsetting People, & Disrupting The Status Quo Sep 19, 2021
    Show notes

    CardioNerds (Amit Goyal, Daniel Ambinder) and Dr. Mark Belkin, (CardioNerds Correspondent) and Dr. Shirlene Obuobi (CardioNerds Ambassador) from University of Chicago are honored to bring to you the Dr. Milton Packer perspective on the evolution of the neurohormonal hypothesis as part of The CardioNerds Heart Success Series. In part 1 Dr. Packer discusses taking risks, upsetting people and the ridiculousness of humanity and how stand-up comedy helped contribute and shape his career in cardiovascular medicine. Dr. Packer also discusses how the study of afterload agents in heart failure and the discovery of tachyphylaxis with prazosin helped inspire a long and prosperous career in academic cardiology by changing the status quo. Check out the CardioNerds Heart Failure Success Series Page for more heart success episodes and content! This is a non CME episode. Disclosures: Milton Packer reports receiving consulting fees from Abbvie, Actavis, Amgen, Amarin, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson Health Care Systems Inc., Eli Lilly and Company, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Teva Pharmaceuticals USA Inc. and Theravance Biopharma Inc. CardioNerds Heart Failure Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! This CardioNerds Heart Failure Success Series was created in memory of Dr. David Taylor. We thank our partners at the Heart Failure Society of America which is a multidisciplinary organization working to improve and expand heart failure care through collaboration, education, research, innovation, and advocacy. Its members include physicians, scientists, nurses, nurse practitioners, and pharmacists. Learn more at hfsa.org.


    145. ACHD: Pregnancy and Congenital Heart Disease with Dr. Carole Warnes Sep 14, 2021
    Show notes

    CardioNerds (Amit Goyal and Daniel Ambinder), ACHD series co-chair Dr. Agnes Koczo (UPMC), and ACHD FIT lead Dr. Katia Bravo (UCLA) join ACHD expert Dr. Carole Warnes (Professor of Medicine and founder of the Adult Congenital Heart Disease Clinic at Mayo Clinic), to discuss adult congenial heart disease and pregnancy. They cover preconception counseling in women with congenital heart disease, appropriate risk stratification to estimate maternal and neonatal morbidity using existing tools and an individualized care approach and preparation for a multidisciplinary delivery plan. Audio editing by CardioNerds Academy Intern, Dr. Leticia Helms. The CardioNerds Adult Congenital Heart Disease (ACHD) series provides a comprehensive curriculum to dive deep into the labyrinthine world of congenital heart disease with the aim of empowering every CardioNerd to help improve the lives of people living with congenital heart disease. This series is multi-institutional collaborative project made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Josh Saef, Dr. Agnes Koczo, and Dr. Dan Clark. The CardioNerds Adult Congenital Heart Disease Series is developed in collaboration with the Adult Congenital Heart Association, The CHiP Network, and Heart University. See more Claim free CME for enjoying this episode! Disclosures: None Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Adult Congenital Heart Disease PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Women with congenital heart disease can safely carry a pregnancy if appropriate risk stratification and management is performed by an expert multidisciplinary cardio-obstetrics team.There are a myriad of hemodynamic and vascular changes which impact congenital cardiac physiology and evolve throughout the different stages of pregnancy. Therefore, planning is key. An evaluation of heart rate response to exercise and optimization of potential factors that could worsen during pregnancy, such as arrhythmias, are recommended.Maternal morbidity & mortality risk-stratification systems such as the modified WHO, CARPREG or ZAHARA criteria are helpful starting points. Ultimately, each patient requires individualization given the heterogeneity that exists among congenital heart defects.Vaginal delivery is generally preferred over C-section from a cardiac standpoint. An assisted second stage of labor during the period of greatest hemodynamics changes should also be considered if vaginal delivery is pursued. Show notes Pregnancy and Adult Congential Heart Disease: Created by Dr. Katia Bravo and Dr. Teodora Donisan and reviewed by Dr. Candice Silversides 1. Why is preconception counseling important in women with congenital heart disease and what does it entail? Ensuring women with congenital heart disease are optimized prior to conception decreases maternal and neonatal complications. For this reason, preconception counseling is paramount for these patients.In addition, counseling leads to patients making more informed decisions about family planning.The integral parts of preconception counseling include: (1) discussing the current anatomical and physiological status, (2) discussing possible complications during pregnancy specific to the patient's congenital heart defect (with genetic counseling referral if appropriate), (3) evaluating cardiac medications, taking into account benefits vs teratogenic potential, (4) discussing and planning for necessary pre-pregnancy tests or interventions (exercise stress testing is an important tool in evaluating how the patient will tolerate the stressors of pregnancy), (5) organizing antepartum care with high-risk obstetrics teams, (6) discussing location, timing and mode of delivery, (7) discussing alternative options to carrying a pregnancy in women who are at extreme risk (ie Fontan physiology, Eisenmenger syndrome) and (8) discussing postpartum contraception. 2. How do we risk stratify women with congenital heart disease who are contemplating pregnancy? An expert evaluation by an ACHD specialist is recommended using a thorough clinical and hemodynamic assessment centered around the individual patient and her values. Several risk prediction tools are available and should be used as a starting point. These include the modified World Health Organization (mWHO) classification, risk factors derived from CARPREG II (CARdiac disease in PREGnancy II), and ZAHARA (acronym based on Dutch translation for Pregnancy in congenital heart defects - Zwangerschap bij Aangeboren HARtAfwijkingen I) studies. The mWHO classification groups congenital hearts conditions into class I to IV, with higher classes indicating higher predicted risk of cardiovascular maternal morbidity and mortality.The CARPREG II risk prediction index assigns points based on a number of different predictors including prior cardiac events or arrhythmias, baseline New York Heart Association Class III-IV or cyanosis, presence of a mechanical valve, ventricular dysfunction, high risk left-sided valve disease or left ventricular outflow tract obstruction, pulmonary hypertension, and coronary artery disease or high-risk aortopathies.The ZAHARA risk score also considers sub-pulmonary atrioventricular valve regurgitation and cardiac medications before pregnancy as additional risk factors as well. 3. What are the potential fetal/neonatal risks associated with pregnancy in congenital heart conditions? Some of the risks include spontaneous abortion, premature birth, small for gestational age neonate, and congenital heart disease in the baby (which may be different than maternal CHD (see Table 1). Most of these are related to maternal heart failure; however other complications such as arrhythmias, endocarditis, thromboembolic events, and medication adverse effects predispose to neonatal complications. Specifically, women with uncorrected cyanotic heart disease and pulmonary hypertension with saturation levels ≤ 85% reach a live birth rate of only 12%. Table 1. Recurrence rate for congenital heart lesions in affected mothers. LesionRecurrence rateAtrial septal defect4-6%Ventricular septal defect6-10%Atrioventricular septal defect11.5-14%Coarctation of the aorta4-6.5%Left ventricular outflow tract obstruction8-18%Right ventricular outflow tract obstruction4-6.5%Tetralogy of Fallot2-2.5%Transposition of the great arteries2%Congenitally corrected transposition of the great arteries3-5%Univentricular hearts21% What should a multidisciplinary delivery plan include? Detailed delivery planning should be undertaken prior to expected delivery date to plan for obstetric anesthesia and analgesia, inpatient peripartum management (level of acuity, need for bubble filters in cases of shunts, avoidance of excessive volume load, infective endocarditis prophylaxis, mode of delivery), as well as postpartum care and discharge planning including post-partum contraception. Maternal and Neonatal Risk by Congenital Lesion AnatomyMaternal RiskFetal/ Neonatal riskPoints to considerRight ventricular outflow tract obstruction or regurgitation- Increased pregnancy-induced preload can promote RV dilatation and heart failure- Preterm labor - Small for gestational ageUsually well tolerated during pregnancyLeft-sided obstructive lesions- Heart failure in patients with severe symptomatic AS with volume expansion in pregnancy - Small for gestational ageBalloon valvuloplasty in severe, symptomatic casesSystemic right ventricle- Heart failure - Atrial arrhythmias - Worsening systemic tricuspid regurgitation- 25-50% prematurity - Small for gestational ageSystemic RV function may be impacted by repeat pregnanciesCoarctation of the aorta- Hypertensive disorders of pregnancy - Heart failure- Small for gestational age- Hormonal changes may impact aortic vasculature into the postpartum periodEbstein’s anomaly- Cyanosis - Arrhythmias can be triggered by increased preload - Related to maternal oxygen saturation- Use bubble filters to avoid paradoxical emboli (high coexistence of ASD)Fontan circulation- Atrial arrhythmias can be triggered by increased preload - Thromboembolism due to hormonal changes - Discuss termination of pregnancy in failing Fontan - 40-70% prematurity - Small for gestational ageBaseline oxygen saturation is the most important marker for fetal outcomes.Eisenmenger syndrome Also see Episode #124 – Pregnancy & Pulmonary Hypertension with Dr. Candice Silversides - Mortality 20-40%. - Discuss termination of pregnancy-Right ventricular failure from increased preload -Thromboembolism due to hormonal changesAortopathy Also see Episode #126 – Pregnancy & Aortic Disorders with Dr. Nupoor Narula- Hormonal changes impact aortic vasculature and can led to accelerated aortic enlargement - 10% risk aortic dissection risk (usually third trimester or postpartum) in Marfan syndrome with root diameter >40 mm, rapid dilation or previous dissection of the ascending aorta- 15% premature delivery due to premature rupture of membranes. - In cases of dissection, fetal demise can occur.Prophylactic aortic root replacement considered before pregnancy if diameter >40 mm, or smaller with rapid increase in dimensions, family history of dissection, or concomitant severe AI References Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. Apr 2 2019;139(14):e698-e800. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000603European Society of G, Association for European Paediatric C, German Society for Gender M, et al....


    Previous 1 31 32 33 34 35 48 Next

    Related Podcasts

    Fresh Air

    1

    Fresh Air Arts
    Twenty Thousand Hertz

    2

    Twenty Thousand Hertz Arts
    The Black Tapes

    3

    The Black Tapes Arts
    Snap Judgment

    4

    Snap Judgment Arts
    Here’s The Thing with Alec Baldwin

    5

    Here’s The Thing with Alec Baldwin Arts
    The NoSleep Podcast – Creative Reason Media Inc.

    6

    The NoSleep Podcast – Creative Reason Media Inc. Arts
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights